Scientists are increasingly examining retatrutide, a innovative drug developed by Eli Lilly, as a potential step in weight management. Unlike many earlier approaches, retatrutide is a double -action receptor targeting simultaneously GLP-1 and GIP, chemicals that influence satiety and glucose contro